DermTech Inc

DermTech, Inc. engages in the development and sale of products for the diagnosis and treatment of skin diseases. It markets and develops products that facilitate diagnosis and management of various skin conditions, including skin cancer, inflammatory diseases, and aging-related conditions. Its products and services include melanoma test, smart sticker, and telemedicine option for melanoma test. The company was founded in 1995 and is headquartered in La Jolla, CA.

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q3 2024

DermTech sees growth in test volumes despite revenue decline

DermTech's Q4 performance reflects growth in coverage and billable sample volumes, despite a decline in total revenue.
The company's strengths lie in expanding market acceptance, stabilized ASPs, and efforts to reduce payer friction.
Challenges include revenue diversification, leadership transition, and uncertainties in ASP trends, while opportunities exist in payer discussions and operational enhancements.

DermTech Inc reports revenue growth and volume increases in Q1

DermTech Inc's Q1 2023 performance showed revenue growth and volume increases, with a focus on stabilizing ASP and driving reimbursed volumes.
While facing challenges with flat DMT volumes and frustration over national payers' views, the company is optimistic about broader acceptance and cost-saving initiatives.
Opportunities lie in TRUST 2 study results influencing payer discussions, momentum with other payers, and targeting physicians with aligned payer mixes.

DermTech reports mixed Q2 results, focuses on revenue growth

DermTech faces challenges with flat DMT volumes and higher operating expenses but is leveraging strengths in insurance partnerships and revenue prioritization.
Opportunities lie in the growth potential of the DMT, expanding coverage, and optimizing sales strategies for revenue enhancement.
Overall, DermTech's financial performance in Q2 2023 reflects a strategic focus on revenue growth amidst operational challenges.

DermTech reports improved Q3 performance, eyes TRUST 2 study impact

DermTech's Q3 2023 performance showcased positive trends in ASP, revenue, and operational efficiency, despite a net loss.
Strategic strengths in sales team alignment, clinical value emphasis, and liquidity position the company well for future growth.
Challenges lie in maintaining test volumes, sustaining margins, and addressing cost reductions and effective payer communications.
Opportunities include TRUST 2 study results, legislative efforts, and focusing on reimbursed tests for revenue growth.

DermTech Inc reports robust Q4 growth and strategic cost reductions

DermTech Inc's Q4 2023 performance showcased strong growth in key metrics and financial health.
The company's focus on precision genomics and cost efficiencies positions it well for future success.
Challenges lie in sustaining revenue growth, optimizing expenses, and engaging payers effectively.
Opportunities abound in expanding reimbursed tests, revenue, and market presence for long-term growth.

The full company name is Design Media Technology, Inc.

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.12% and 19.52%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q4 Loss, Tops Revenue Estimates

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its fourth-quarter and full-year 2022 financial results. The Company also announced that Dr. John Dobak expects to step away from his role as president, chief executive officer and director under a planned transition.

DermTech Reports Fourth-Quarter and Full-Year 2022 Financial Results; Company Announces CEO Transition Plan

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Thursday, March 2, 2023 at 5:00 p.m. Eastern Time (ET) to discuss the Company's fourth-quarter 2022 operating and financial results. In advance of the call on March 2, 2023, DermTech will issue its fourth-quarter 2022 earnings press release.

DermTech Announces Release Date for Fourth-Quarter 2022 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that U.S. General Services Administration has recommended the Company's foundational assay included in the DermTech Melanoma Test (DMT) for coverage by the Veterans Health Administration (VHA). The VHA is the largest integrated health care system in the U.S.

DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by the Veterans Health Administration

LA JOLLA, Calif.--( BUSINESS WIRE )--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from two commercial payers comprising a Blues plan in Hawaii and a physician-founded, member-focused and community-based not-for-profit health plan in New York. The coverage policies resulted from an independent technology assessment by the second largest laboratory benefits manager in the U.S. and are similar to the Medicare coverage policy of the Company's foundational assay included in the DermTech Melanoma Test (DMT).

DermTech Adds Approximately 1.2 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

The company's skin diagnostic test, dubbed DMT, has an uncanny ability to pick up the highly prevalent skin cancer, melanoma. Commercialization has been modest due to various launch barriers. Nevertheless, the company is exerting strong efforts to improve success.

DermTech: Momentum Rising With TRICARE

This beaten-down healthcare stock has started the new year off with a bang.

This Under-the-Radar Stock Has Tripled in 2023 -- and Could Have More Room to Run

LA JOLLA, Calif.--( BUSINESS WIRE )--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced that the Defense Health Agency's Lab Joint Working Group has recommended the Company's foundational assay included in the DermTech Melanoma Test (DMT) for coverage by TRICARE. TRICARE is the health care program for uniformed service members, retirees and their families around the world.

DermTech Announces the Foundational Assay of Its DermTech Melanoma Test (DMT) Is Recommended for Coverage by TRICARE

LA JOLLA, Calif.--( BUSINESS WIRE )--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced favorable coverage policies from four commercial payers including Blue Cross Blue Shield of North Carolina (BCBS NC), Blue Cross Blue Shield of South Carolina (BCBS SC), Blue Cross Blue Shield of Louisiana (BCBS LA) and Blue Cross Blue Shield of Kansas City (BCBS KC). These coverage policies were announced pursuant to an independent technology assessment by the second largest laboratory benefits manager in the U.S. and are similar to the policy issued by Medicare for coverage of the Company's foundational assay for the DermTech Melanoma Test (DMT). In addition, the Company recently entered into an agreement with a Blues plan in Michigan.

DermTech Adds Approximately 13 Million Covered Lives for the Foundational Assay of Its DermTech Melanoma Test (DMT)

LA JOLLA, Calif. & PHOENIX--( BUSINESS WIRE )--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today an agreement with Sonora Quest Laboratories (Sonora Quest), Arizona's leading diagnostic laboratory, to expand access to enhanced melanoma detection. As a result of the agreement, Sonora Quest will be the exclusive laboratory in Arizona to offer the DermTech Melanoma Test to its vast network of healthcare providers.

DermTech and Sonora Quest Laboratories Expand Access to Innovative Melanoma Detection Test

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 3.03% and 26.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q3 Loss, Misses Revenue Estimates

DermTech, Inc. (NASDAQ:DMTK ) Q3 2022 Earnings Conference Call November 3, 2022 5:00 PM ET Company Participants Steve Kunszabo - Head of IR John Dobak - President and CEO Kevin Sun - CFO Conference Call Participants Thomas Flaten - Lake Street Capital Operator Good day, and thank you for standing by. Welcome to the DermTech Third Quarter 2022 Financial Results Call.

DermTech, Inc. (DMTK) Q3 2022 Earnings Call Transcript

DermTech Reports Third-Quarter 2022 Financial Results

DermTech Announces Release Date for Third-Quarter 2022 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at the Biomarkers & Precision Medicine USA Congress, held from Oct. 3-4 in San Diego. The 6th annual event featured industry-leading speakers from the pharma, biotech and academic spaces, sharing new case studies, innovative data and industry outlooks. Erica Montano, Ph.D., a DermT

DermTech Presents on Translational Medicine to Revolutionize Dermatologic Care at the Biomarkers & Precision Medicine USA Congress

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced its presentation at Outsourcing in Clinical Trials Southern California, held from Sept. 28-29 in San Diego. The 9th annual event featured industry-leading speakers from the global clinical trial space. Elisa Lanni, M.S., DermTech Stratum senior project manager, discussed the current challenges of patie

DermTech Presents on Technological Advances and the Value of Decentralization at Outsourcing in Clinical Trials Southern California

Lemonade

These two stocks have sky-high potential.

Will These Two Stocks Boom or Bust?

Today, we take our first look at DermTech, Inc., a small molecular testing concern. The company is seeing some sales traction and the stock sells for less than cash value, but DermTech's cash burn rate is more than concerning.

Diving Into DermTech

DermTech, Inc. (NASDAQ:DMTK ) Q2 2022 Earnings Conference Call August 8, 2022 5:00 PM ET Company Participants Steve Kunszabo - Head of Investor Relations John Dobak - President & Chief Executive Officer Kevin Sun - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Griffin Soriano - William Blair Jacob Johnson - Stephens Max Masucci - Cowen François Brisebois - Oppenheimer Thomas Flaten - Lake Street Capital Markets Operator Good day. My name is Chantel, and I'll be your conference operator today.

DermTech, Inc. (DMTK) CEO John Dobak on Q2 2022 Results - Earnings Call Transcript

DermTech, Inc. (DMTK) delivered earnings and revenue surprises of 2.94% and 14.49%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DermTech, Inc. (DMTK) Reports Q2 Loss, Lags Revenue Estimates

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today reported its second-quarter 2022 financial results and updated its full-year 2022 outlook. “We continued to set records for many of our key operating and financial metrics in the first half of 2022 despite numerous headwinds,” said John Dobak, M.D., CEO, DermTech. “Our sales and marketing team continues to be ve

DermTech Reports Second-Quarter 2022 Financial Results; Company Updates Full-Year 2022 Outlook

DermTech, Inc. (DMTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: DermTech, Inc. (DMTK) Q2 Earnings Expected to Decline

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, has appointed two new members to its senior leadership team. Jennifer Eilemberg has been named chief compliance officer and will oversee the Company's compliance with laws, regulatory requirements, rigorous internal policies and procedures. Steven Stone has stepped into the position of senior vice president of researc

DermTech Appoints Chief Compliance Officer and SVP of Research and Development

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, will host a conference call and webcast on Monday, August 8, 2022 at 5:00 p.m. Eastern Time (ET) to discuss the Company's second-quarter 2022 operating and financial highlights. In advance of the call on August 8, 2022, DermTech will issue its second-quarter 2022 earnings press release. To participate in the teleconfe

DermTech Announces Release Date for Second-Quarter 2022 Financial Results

LA JOLLA, Calif.--(BUSINESS WIRE)--DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced the appointment of Kirk D. Malloy, Ph.D. and Mark C. Capone, M.S. to the Company's board of directors, effective July 18,2022. These appointments expand DermTech's board of directors to eight members. “We are excited to welcome Kirk and Mark as new independent directors,” commented Matt Posard, DermTec

News for DermTech Inc Stock (DMTK)